Resource Logo
AIDS Weekly Plus

Findings from University of California in the Area of HIV/AIDS Reported




 



2013 AUG 12 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Fresh data on Immune System Diseases and Conditions are presented in a new report. According to news reporting originating in San Francisco, California, by NewsRx journalists, research stated, "To compare asymmetric dimethylarginine (ADMA) among HIV-infected and uninfected individuals and to evaluate predictors of ADMA in HIV infection. HIV-infected individuals have high rates of atherosclerosis."

The news reporters obtained a quote from the research from the University of California, "Endothelial dysfunction is central to atherogenesis and is one possible mechanism underlying this increased cardiovascular risk. ADMA is an endogenous inhibitor of endothelial nitric oxide synthase. Among uninfected individuals, higher ADMA levels predict cardiovascular events and mortality. The association between HIV infection, HIV-related factors, and ADMA has not been well described. We compared ADMA in 248 HIV-infected individuals and 50 uninfected controls. We performed multivariable analysis using traditional cardiovascular and HIV-specific factors as covariates to identify factors associated with ADMA. HIV-infected men were older, less often Caucasian, more hypertensive, and had lower HDL than uninfected men. The median duration of HIV infection was 13 years, median CD4+ count was 592 cells/mu L, 76% had an undetectable viral load, and 76% were on antiretroviral therapy. ADMA levels were modestly higher in HIV-infected individuals than controls [median (IQR): 0.46 mu M (0.41-0.52) vs. 0.44 mu M (0.38-0.46), p = 0.019], but the association lost statistical significance after controlling for cardiovascular risk factors (+0.028 mu M, p = 0.054). Lower CD4+ count and both detectable and higher viral load were independently associated with increased ADMA. ADMA levels were modestly elevated in the setting of HIV infection. Notably, a greater HIV-associated inflammatory burden, as evidenced by lower CD4+ counts and higher viral loads, was associated with increased ADMA levels."

According to the news reporters, the research concluded: "Our findings suggest that HIV infection impairs endothelial function and predisposes to atherosclerosis through chronic inflammation and subsequent accumulation of ADMA."

For more information on this research see: Elevated levels of asymmetric dimethylarginine are associated with lower CD4+count and higher viral load in HIV-infected individuals. Atherosclerosis, 2013;229(1):246-252. Atherosclerosis can be contacted at: Elsevier Ireland Ltd, Elsevier House, Brookvale Plaza, East Park Shannon, Co, Clare, 00000, Ireland. (Elsevier - www.elsevier.com; Atherosclerosis - www.elsevier.com/wps/product/cws_home/522790)

Our news correspondents report that additional information may be obtained by contacting R.V. Parikh, University of California, Dept. of Epidemiol & Biostat, San Francisco, CA 94143, United States (see also Immune System Diseases and Conditions).

Keywords for this news article include: HIV/AIDS, California, Cardiology, Viral Load, RNA Viruses, Retroviridae, San Francisco, United States, Cardiovascular, HIV Infections, Vertebrate Viruses, Primate Lentiviruses, North and Central America, Microbiological Techniques, Virus Physiological Phenomena, Viral Sexually Transmitted Diseases

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC



 


Copyright © 2013 -AIDS Weekly Plus, Publisher. All rights reserved to Charles Henderson, Publisher. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633- 4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX:(205) 995-1588 Visit AIDS WEEKLY PLUS.



Information in this article was accurate in August 12, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.